Edward Newman
Associate Professor
Cancer Biology
Beckman Research Institute
United States of America
Biography
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy
Research Interest
Cancer Biology Developmental Cancer Therapeutics Program Comprehensive Cancer Center Co-leaders Early Therapeutic Disease Team Leukemia Disease Team Lymphoma Disease Team
Publications
-
CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin
-
Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine. Cancer chemotherapy and pharmacology. 2015 Mar 1;75(3):537-46.
